CN103316270A - Preparation method of powder of medicine for treating postnatal perineum mucosal lesion - Google Patents
Preparation method of powder of medicine for treating postnatal perineum mucosal lesion Download PDFInfo
- Publication number
- CN103316270A CN103316270A CN2013102678541A CN201310267854A CN103316270A CN 103316270 A CN103316270 A CN 103316270A CN 2013102678541 A CN2013102678541 A CN 2013102678541A CN 201310267854 A CN201310267854 A CN 201310267854A CN 103316270 A CN103316270 A CN 103316270A
- Authority
- CN
- China
- Prior art keywords
- perineum
- preparation
- medicine
- powder
- dry extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses a preparation method of powder of a medicine for treating postnatal perineum mucosal lesion, which is used for solving the problems in treatment by use of a medicine for treating postnatal perineum mucosal lesion. The preparation method is characterized by comprising the following steps of: (1) performing reduced-pressure distillation on the coarse powder of cortex erythrinae, radix ranunculi ternati and radix ephedrae, and extracting volatile oil; (2) performing reduced-pressure decoction on gastrodia elata to obtain filtrate; (3) decocting trikeraia hookeri, alpinia japonica, herba taxilli, coking malt, coking medicated leaven, spina gleditsiae, peach gum and rhizoma anemones altaicae and the dregs obtained in the step (1) with water to obtain filtrate for later use; (4) combining the filtrates obtained by the steps (2) and (3), performing reduced-pressure concentration to obtain a dry extract, and grinding the dry extract to obtain dry extract powder; and (5) spraying the volatile oil obtained in the step (1) into the dry extract powder obtained in the step (4), mixing uniformly, screening by a 100-mesh sieve, and sub-packing to obtain the powder. Clinical experiments prove that the medicine for treating postnatal perineum mucosal lesion has the characteristics of good curative effect and high safety, and deserves clinical application and popularization.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of powder preparation method for the treatment of postpartum perineum mucosa infection medicine.
Background technology
Puerperal, uterus, cervix uteri, vagina, perineum can produce a series of variations because hormonal readiness descends rapidly.For perineum, during childbirth, because fetus extruding vagina collar extension.Usually cause that perineum is congested, edema, or laceration is in various degree arranged, fade away in after this 7 days.Meanwhile, pleat minimizing on every side also can appear in perineal position, and intravaginal mucosa is smooth, and the mucosa phylactic power defensive power reduces the symptoms such as easy secondary pruritus vulvae, vaginal dryness.In general, at short notice, vaginal mucosa is not easy to return to fully pregravidic situation, only after stopping to breast-feed, and menstrual onset, ovarian function is normal, and under functions of hormones, it is normal that vaginal mucosa is just recovered gradually.
Be for symptom mostly for the postpartum perineum mucosa infection at present, as give 50% magnesium sulfate dressing to alleviate edema, the flushing of 1:5000 potassium permanganate liquid cooperates 0.2% metronidazole solution soak to protect from infection.But in fact, the basic pathology owing to morbidity is: puerperal, estrogen level descended rapidly, caused the relative atrophy of vaginal wall, glycogen content reduces in the mucosa attenuation, epithelial cell, and intravaginal Ph value rises, local resistance reduces, and pathogenic bacterium are easily invaded breeding and cause and inflammation.And magnesium sulfate, potassium permanganate liquid flushing liquor also are a kind of stimulations for mucosa, can solve early stage myxedema problem, but unfavorable on the contrary to long-term prognosis.
And Chinese medicine perineum Wet-dressing agent is many, but be mostly for Women of Childbearing Age, contain Radix Sophorae Flavescentis, Fructus Cnidii, the Fructus Kochiae, Rhizoma Smilacis Glabrae etc. in the prescription except the medicine of noxious dampness more, and mainly being the mucosa attenuation, the cause of postpartum perineum mucosa infection causes, the medicine external of above dispelling the damp pathogen with drugs of bitter in taste and cold in nature, then irritates nucous membrane more causes aggravation.And the said medicine bitter cold is unfavorable for postpartum recovery.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provides a kind of curative effect certainly and the powder of the treatment postpartum perineum mucosa infection medicine that side effect is little.
The technical scheme that the present invention solves its technical problem is: a kind of powder for the treatment of postpartum perineum mucosa infection medicine is characterized in that being prepared from by the crude drug of following weight proportion: 10 ~ 30 parts of Cortex erythrinaes, 6 ~ 12 parts of Herba Chlorophyti Laxis, go back 3 ~ 10 parts in bobbin, 6 ~ 12 parts of Alpinia japonica (Thunb.) Miq.s, 3 ~ 10 parts of Herba Taxillis, 6 ~ 12 parts of Radix Ranunculi Ternatis, 6 ~ 12 parts of Fructus Hordei Germinatus (parched to brown)s, 6 ~ 12 parts of Massa Medicata Fermentata (parched to brown), 6 ~ 12 parts of Radix Ephedraes, 1 ~ 5 part of Spina Gleditsiae, 3 ~ 10 parts of gumshiraz, 10 ~ 25 parts of Rhizoma Anemones Altaicaes.
Chinese medicine of the present invention can be prepared from by following method:
(1) volatile oil is extracted in Cortex erythrinae, Radix Ranunculi Ternati, the distilling under reduced pressure of Radix Ephedrae coarse powder difference, and mixing for standby use after collecting, the medicinal residues mixing for standby use;
(2) will go back the bobbin decompression and decoct 2 times, each 30min, collecting decoction leaves standstill rear filtration, gets filtrate for later use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Alpinia japonica (Thunb.) Miq., Herba Taxilli, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Spina Gleditsiae, gumshiraz, Rhizoma Anemones Altaicae and the step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction left standstill rear filtration, gets filtrate for later use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to get dry extract;
(5) gained volatile oil in the step 1 is sprayed in the step 4 gained dry extract, mixing is crossed 100 mesh sieves, and packing forms.
The pressure of the distilling under reduced pressure in the above-mentioned steps (1) is 0.1Mpa.
The pressure that decompression in the above-mentioned steps (2) decocts is 0.4Mpa.
The pressure of the concentrating under reduced pressure in the above-mentioned steps (4) is 0.4Mpa.
Wherein said: Cortex erythrinae is bark or the root bark of pulse family Erythrinae Arborescentis Erythrina indica Lam..Nature and flavor are bitter, and are flat.Return liver, kidney channel.But the merit wind-damp dispelling, channels sootheing and network vessel quickening.Wind-damp dispelling, the meridian dredging, parasite killing.
Herba Chlorophyti Laxi is herb or the root of feverfew Prenanthes henryi Dunn Prenanthes henryi Dunn.Bitter in the mouth; Cold in nature.But merit heat-clearing and toxic substances removing; The dissipating blood stasis hemostasis.
Also bobbin is the fruit of orchid Rhizoma Gastrodiae Gastrodia elata Bl..Sweet in the mouth; Cold in nature.But merit tonify deficiency subduing the wind syndrome.Main dizzy; Pupil; The wind syndrome of head headache; The weak breath consumption of essence; Early whitening of beard and hair.
Alpinia japonica (Thunb.) Miq. for Zingiberaceae Alpinia plants Alpinia japonica (Thunb.) Miq. Alpinia japonica Miq., is used as medicine with root stock.Nature and flavor are hot, warm.Return lung, spleen, Liver Channel.But the merit dispelling wind and removing obstruction in the collateral, regulating QI to relieve pain.
Herba Taxilli is the dry stem and branch with leaf of Loranthaceae plant Herba Taxilli Taxillus chinensis (DC.) Danser for Herba Taxilli.Nature and flavor are bitter, sweet, and are flat.Return liver, kidney channel.But the merit invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling, antiabortive unit.
Radix Ranunculi Ternati is the dried root of the little Herba Ranunculi Japonici Ranunculus of ranunculaceae plant ternatus Thunb..Nature and flavor are sweet, hot, temperature.Return liver, lung meridian.But the merit eliminating stagnation, detumescence.
Fructus Hordei Germinatus (parched to brown), for the mature fruit of grass Fructus Hordei Vulgaris Hordeum vulgare L. through the drying of germinateing, fry to burnt brown according to the method for frying, cool sieve dedust bits.Nature and flavor are sweet, and are flat.Return spleen, stomach warp.But the merit promote qi circulation digestion promoting, spleen benefiting and stimulating the appetite moves back newborn relieving distension.
Massa Medicata Fermentata (parched to brown), for the medicines such as Herba polygoni hydropiperis, Herba Artemisiae Annuae, Semen Armeniacae Amarum add flour or wheat bran mixed after, through the herbal leaven that fermentation forms, fry to burnt brown according to frying method.The sweet suffering of nature and flavor, temperature.Enter spleen, stomach warp.But the merit invigorating the spleen and regulating the stomach is in the accent that helps digestion.
Radix Ephedrae is the dry root and rhizome of Ephedraceae plant plait Herba Ephedrae Ephedra sinica Stapf or epheday intermedia Ephedra intermedia Schrenk et C. A. Mey..Nature and flavor are sweet, and are flat.GUIXIN, lung meridian.But merit hidroschesis.
Spina Gleditsiae is the dry Spina jujubae of leguminous plant Fructus Gleditsia Gleditsia sinensis Lam..Nature and flavor are hot, temperature.Return liver, stomach warp.The merit poison holding of can subsiding a swelling, evacuation of pus, parasite killing.
Gumshiraz is rosaceous plant peach Prunus persica (L.) Batsch, the resin that flows out on the trunk.Nature and flavor are bitter, flat.Merit can be invigorated blood circulation, and QI invigorating is quenched the thirst.
Rhizoma Anemones Altaicae for Ranunculaceae thimbleweed anemone altaica Anemone altaica Mey., is used as medicine with root stock.Nature and flavor are hot, temperature.But the merit causing resuscitation with aromatic drugs reduces phlegm, and calms the nerves.
Composition principle: the postpartum perineum mucosa infection often reduces because of the ovarioestrogen level, the attenuation of vaginal wall mucosa, and glycogen content reduces in the epithelial cell, and intravaginal Ph value rises, and local resistance reduces, and pathogenic bacterium are easily invaded breeding and cause and inflammation.Cardinal symptom is that vaginal secretions increases and pruritus vulvae, burning sensation.At present the colpitic suppository of Chinese traditional treatment, Wet-dressing agent are many, but be mostly for Women of Childbearing Age, contain Radix Sophorae Flavescentis, Fructus Cnidii, the Fructus Kochiae, Rhizoma Smilacis Glabrae etc. in the prescription except the medicine of noxious dampness more, and mainly being the mucosa attenuation, the cause of postpartum perineum mucosa infection causes, the medicine external of above dispelling the damp pathogen with drugs of bitter in taste and cold in nature, then irritates nucous membrane more causes aggravation.The object of the invention is to avoid using the dispelling the damp pathogen with drugs of bitter in taste and cold in nature medicine, and reduce from estrogen level, the vaginal wall atrophy, this pathological change angle of mucosa attenuation is started with, and reaches the purpose of " treatment of disease must aim at its pathogenesis ".
Compared with prior art, the present invention has following characteristics:
1, prescription is unique, avoids using the dispelling the damp pathogen with drugs of bitter in taste and cold in nature antipruritic agent: get Cortex erythrinae in the side, go back bobbin and be monarch, Cortex erythrinae dosage of record is in " China's book on Chinese herbal medicine ": " taking orally: fry in shallow oil soup, 6-12g "; The inventor experimental results show that (10 ~ 30g) can recover by specific promotion vaginal wall mucosa middle heavy dose of Cortex erythrinae, and go back bobbin the similar plants estrogen action is arranged, but this act as two-ways regulation, can not produce the low differentiation of the excessive stimulation reproductive system of estrogen cell;
2, characteristic of the present invention also is balance and restriction: record Cortex erythrinae in 1. " must joining book on Chinese herbal medicine ": " insufficiency of blood heated person forbidding ", but puerperal often with the resembling of deficiency of YIN-blood, and use Cortex erythrinae this moment, its hematozemia of fearing is then arranged and causes the yin asthenia generating intrinsic heat appearance; Therefore add Herba Chlorophyti Laxi and go back bobbin, also but the training of bobbin merit tonify deficiency is basic, and can prevent that Cortex erythrinae from consuming cloudy blood and liver-wind stirring up internally, and the Herba Chlorophyti Laxi bitter in the mouth is cold in nature, utilize its cold heated that prevents on the one hand, but on the other hand its merit dissipating blood stasis hemostasis there is out entire merit in blood system, prevent the Cortex erythrinae moving blood of wandering away, also can not affect Cortex erythrinae simultaneously and work orderly effect; 2. the use of Rhizoma Anemones Altaicae is among the we: a causing resuscitation with aromatic drugs and benefaction, and two Yin Yang balancings, with the bitter cold of balance we invasion by pathogenic cold medicine of a cold nature thing, inventor's clinical research finds that Rhizoma Anemones Altaicae activates yang and do not consume the moon in addition, is suitable for using puerperal; The application characteristic of Rhizoma Anemones Altaicae is in the prescription of the present invention: measure larger (" consumption in the Chinese pharmacopoeia is 1.5-6g), so too disperse for preventing, get again Radix Ephedrae convergence assistant system;
3, the supplementary drug thing is fewer but better: get the Alpinia japonica (Thunb.) Miq. assistant in the side and help Herba Chlorophyti Laxi, heat conduction is descending; Radix Ranunculi Ternati and Herba Chlorophyti Laxi collocation have the effect of detoxifcation, eliminating stagnation, pain relieving; The Herba Taxilli assistant helps goes back the bobbin vital base and primordial QI consolidating; Gumshiraz is invigorated blood circulation, and helps medicine to stay in mucomembranous surface, promotes to absorb;
4, inventor's clinical research is found, the solid protection gastric qi helps the drug disease process control of postpartum perineum mucosa infection and recovery, so select Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown) spleen benefiting and stimulating the appetite;
5, Spina Gleditsiae is the supplementary drug thing, in " China book on Chinese herbal medicine " record consumption be: " for oral administration: as to fry in shallow oil soup, 6 ~ 12g ", inventor's experimental study are found, get low dose of Spina Gleditsiae decocting liquid and can improve the vaginal mucosa cytoactive that exsomatizes.
6, the thing homogeneous medicine multiple-effect of getting it filled in the side helps to reduce drug kinds and consumption, does not increase local excitation;
7, medicine material consumption of the present invention is groped to sum up to draw through the inventor in a large number, and each raw material consumption is for all to have preferably curative effect in the following weight parts scope;
8, go back the fruit that bobbin is the orchid Rhizoma Gastrodiae, comparing with Rhizoma Gastrodiae, go back the Esterified Enzyme isozyme (esterase isoenzyme) that bobbin contains, may be the key of its performance phytoestrogen effect, and inventor's experiment draws, and goes back bobbin Esterified Enzyme isozyme content after decompression decocts higher.
The specific embodiment
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, the crude drug weight proportion: Cortex erythrinae 20g, Herba Chlorophyti Laxi 10g, go back bobbin 6g, Alpinia japonica (Thunb.) Miq. 10g, Herba Taxilli 6g, Radix Ranunculi Ternati 10g, Fructus Hordei Germinatus (parched to brown) 10g, Massa Medicata Fermentata (parched to brown) 10g, Radix Ephedrae 10g, Spina Gleditsiae 2g, gumshiraz 6g, Rhizoma Anemones Altaicae 20g.
The preparation method of embodiment 1 is: with Cortex erythrinae, Herba Chlorophyti Laxi, go back bobbin, Alpinia japonica (Thunb.) Miq., Herba Taxilli, Radix Ranunculi Ternati, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Radix Ephedrae, Spina Gleditsiae, gumshiraz, Rhizoma Anemones Altaicae mixing and water adding and decoct, get filtrate after 30 minutes, medicinal residues add water continuation decoction and get filtrate after 20 minutes, twice filtrate merges washout, once a day.
Embodiment 2, the crude drug weight proportion: 10 parts of Cortex erythrinaes, 6 parts of Herba Chlorophyti Laxis, go back 3 parts in bobbin, 6 parts of Alpinia japonica (Thunb.) Miq.s, 3 parts of Herba Taxillis, 6 parts of Radix Ranunculi Ternatis, 6 parts of Fructus Hordei Germinatus (parched to brown)s, 6 parts of Massa Medicata Fermentata (parched to brown), 6 parts of Radix Ephedraes, 1 part of Spina Gleditsiae, 3 parts of gumshiraz, 10 parts of Rhizoma Anemones Altaicaes.
Embodiment 3, the crude drug weight proportion: 20 parts of Cortex erythrinaes, 10 parts of Herba Chlorophyti Laxis, go back 6 parts in bobbin, 10 parts of Alpinia japonica (Thunb.) Miq.s, 6 parts of Herba Taxillis, 10 parts of Radix Ranunculi Ternatis, 10 parts of Fructus Hordei Germinatus (parched to brown)s, 10 parts of Massa Medicata Fermentata (parched to brown), 10 parts of Radix Ephedraes, 2 parts of Spina Gleditsiaes, 6 parts of gumshiraz, 20 parts of Rhizoma Anemones Altaicaes.
Embodiment 4, the crude drug weight proportion: 30 parts of Cortex erythrinaes, 12 parts of Herba Chlorophyti Laxis, go back 10 parts in bobbin, 12 parts of Alpinia japonica (Thunb.) Miq.s, 10 parts of Herba Taxillis, 12 parts of Radix Ranunculi Ternatis, 12 parts of Fructus Hordei Germinatus (parched to brown)s, 12 parts of Massa Medicata Fermentata (parched to brown), 12 parts of Radix Ephedraes, 5 parts of Spina Gleditsiaes, 10 parts of gumshiraz, 25 parts of Rhizoma Anemones Altaicaes.
The Chinese medicine of embodiment 2 ~ 4 can be prepared from by following method:
(1) volatile oil is extracted in Cortex erythrinae, Radix Ranunculi Ternati, the distilling under reduced pressure of Radix Ephedrae coarse powder difference, and mixing for standby use after collecting, the medicinal residues mixing for standby use;
(2) will go back the bobbin decompression and decoct 2 times, each 30min, collecting decoction leaves standstill rear filtration, gets filtrate for later use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Alpinia japonica (Thunb.) Miq., Herba Taxilli, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Spina Gleditsiae, gumshiraz, Rhizoma Anemones Altaicae and the step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction left standstill rear filtration, gets filtrate for later use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to get dry extract;
(5) gained volatile oil in the step 1 is sprayed in the step 4 gained dry extract, mixing is crossed 100 mesh sieves, and packing forms.
In the prioritization scheme, the pressure of the distilling under reduced pressure in the described step (1) is 0.1Mpa; The pressure that decompression in the described step (2) decocts is 0.4Mpa; The pressure of the concentrating under reduced pressure in the described step (4) is 0.4Mpa.
Effective combination of said medicine is coordinated mutually, effectively reach the purpose for the treatment of postpartum perineum mucosa infection medicine, and side effect is less.The above results is the clinical data sufficient proof, and interrelated data is as follows.
1 object and method.
1.1 object.
1 data and method.
1.1.1 case is selected: in January, 2011 ~ 2013 are diagnosed as postpartum perineum mucosa infection 148 examples year June, are the full-term normal delivery primipara.Get rid of trichomonal vaginitis, monilial vaginitis, urine is cultivated negative.
1.1.2 diagnostic criteria: with reference to " obstetrics and gynecology " (the 5th edition), all cases is all clarified a diagnosis according to medical history, gynecologial examination.Symptom is perineum pruritus, xerosis vulae, the pale or flushing of vaginal mucosa or little petechia is arranged, vaginal health scoring＜15 minutes.
1.1.3 grouping: be divided into matched group 48 examples, soak group 50 example and powder group 50 examples.Compare in age, the state of an illness, the course of disease before three groups of patient treatments, and the difference not statistically significant (P〉0.05), have comparability.
1.2 method.
1.2.1 Therapeutic Method: matched group adopts the flushing of 1:5000 potassium permanganate liquid to cooperate 0.2% metronidazole solution soak, 1 time/d.The soak group is with gained decoct soak in the embodiment of the invention 1,1 time/d.The powder group is blown deposited with gained powder pudendum and intravaginal in the embodiment of the invention 3,1 time/d.7 days is a course for the treatment of.
1.2.2 observation index: conventional inquiry medical history before and after the medication, and according to vaginal health point system (VHS) scoring, determine the doing well,improving situation.
1.2.3 criterion of therapeutical effect: with reference to " obstetrics and gynecology ", recovery from illness: clinical symptoms, sign disappear; Produce effects: clinical symptoms, sign turn for the better by and large; Effectively: clinical symptoms, sign alleviate; Invalid: clinical symptoms, sign are unchanged.
1.2.4 statistical analysis: SPSS 16.0 carries out statistical analysis.Vaginal health scoring single index adopts nonparametric statistics.Measurement data is checked with t, enumeration data χ
2Check.
2 results.
2.1 vaginal symptoms is improved situation: behind the medication 3d, matched group 27.08%(13/48) patient, and soak group and all case pruritus of vagina of powder group, drying, pain symptom all begin to obtain improvement in various degree.Gynecologial examination vaginal wall elasticity increases, and fold is deepened, and the surface is pale, flushing and bleeding are clearly better.According to the vaginal health standards of grading, the vaginal health scoring is the summation of elasticity, wettability, pH, mucosa, 5 project score values of secretions.Scoring is 9.29 ± 2.36 before the soak group patient medication, and the scoring average is 14.27 ± 2.82 behind the medication 7d.Scoring is 10.62 ± 2.72 before the powder group patient medication, and the scoring average is 17.27 ± 2.28 behind the medication 7d.Relatively, (P＜0.05) is all obviously increased in the vaginal health scoring behind two groups of patient treatments before and after the medication.
2.2 three groups of Comprehensive Clinical curative effects relatively: behind the medication 7d, matched group cure rate, obvious effective rate, effective percentage, inefficiency are respectively 31.25%, 43.75%, 18.75%, 6.25%; The cure rate of soak group, obvious effective rate, effective percentage, inefficiency are respectively 56.00%, 34.00%, 10.00%, 0.00%; The cure rate of powder group, obvious effective rate, effective percentage, inefficiency are respectively 70.00%, 18.00%, 12.00%, 0.00%.Three groups relatively, and the cure rate of soak group and powder group, total effective rate are apparently higher than matched group (P＜0.05), and the cure rate of powder group is apparently higher than soak group (P＜0.05).
2.3 adverse reaction rate: obvious adverse reaction does not all appear in three groups of patients.
3. conclusion.
The demonstration of this result of study, soak group of the present invention and powder group treatment postpartum perineum mucosa infection total effective rate are 100%, the cure rate of powder group is higher than the soak group.Have that untoward reaction is light, the higher advantage of safety.
Claims (4)
1. preparation method for the treatment of postpartum perineum mucosa infection drug powder, it is characterized in that, crude drug comprises: Cortex erythrinae, Herba Chlorophyti Laxi, go back bobbin, Alpinia japonica (Thunb.) Miq., Herba Taxilli, Radix Ranunculi Ternati, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Radix Ephedrae, Spina Gleditsiae, gumshiraz, Rhizoma Anemones Altaicae, its preparation method is comprised of following steps:
(1) volatile oil is extracted in Cortex erythrinae, Radix Ranunculi Ternati, the distilling under reduced pressure of Radix Ephedrae coarse powder difference, and mixing for standby use after collecting, the medicinal residues mixing for standby use;
(2) will go back the bobbin decompression and decoct 2 times, each 30min, collecting decoction leaves standstill rear filtration, gets filtrate for later use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Alpinia japonica (Thunb.) Miq., Herba Taxilli, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Spina Gleditsiae, gumshiraz, Rhizoma Anemones Altaicae and the step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction left standstill rear filtration, gets filtrate for later use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to get dry extract;
(5) gained volatile oil in the step 1 is sprayed in the step 4 gained dry extract, mixing is crossed 100 mesh sieves, and packing forms.
2. a kind of preparation method for the treatment of postpartum perineum mucosa infection drug powder according to claim 1, it is characterized in that: the pressure of the distilling under reduced pressure in the described step (1) is 0.1Mpa.
3. a kind of preparation method for the treatment of postpartum perineum mucosa infection drug powder according to claim 1 is characterized in that: the pressure that the decompression in the described step (2) decocts is 0.4Mpa.
4. a kind of preparation method for the treatment of postpartum perineum mucosa infection drug powder according to claim 1, it is characterized in that: the pressure of the concentrating under reduced pressure in the described step (4) is 0.4Mpa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310267854.1A CN103316270B (en) | 2013-07-01 | 2013-07-01 | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310267854.1A CN103316270B (en) | 2013-07-01 | 2013-07-01 | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103316270A true CN103316270A (en) | 2013-09-25 |
| CN103316270B CN103316270B (en) | 2015-03-18 |
Family
ID=49185503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310267854.1A Expired - Fee Related CN103316270B (en) | 2013-07-01 | 2013-07-01 | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103316270B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796760A (en) * | 2016-05-31 | 2016-07-27 | 王海霞 | Preparation method of post-episiotomy external medicine |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1321486A (en) * | 2001-01-10 | 2001-11-14 | 刘从清 | Yinkang lotion |
| CN1768829A (en) * | 2004-11-05 | 2006-05-10 | 郭连英 | Chinese medicine for treating tuberculosis |
| CN102920810A (en) * | 2012-11-20 | 2013-02-13 | 汉仲月 | Mucosa nursing matter for behcet's syndrome |
| CN103285284A (en) * | 2013-07-01 | 2013-09-11 | 庄兰兰 | Medical composition for treating senile vaginitis |
| CN103301353A (en) * | 2013-07-01 | 2013-09-18 | 刘晓晖 | Pharmaceutical composition for treating atrophic vaginitis |
| CN103301373A (en) * | 2013-07-01 | 2013-09-18 | 丁霄雁 | Pharmaceutical composition for treating postpartum perineal mucosal lesions |
| CN103301374A (en) * | 2013-07-01 | 2013-09-18 | 巩春梅 | Pharmaceutical composition for treating postpartum non-specificity vaginitis |
| CN103330896A (en) * | 2013-07-01 | 2013-10-02 | 巩春梅 | Preparation method of powder for treating postpartum nonspecific vaginitis |
| CN103356932A (en) * | 2013-07-01 | 2013-10-23 | 张世叶 | Medicine composition for treating vulva squamous cell hyperplasia |
-
2013
- 2013-07-01 CN CN201310267854.1A patent/CN103316270B/en not_active Expired - Fee Related
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1321486A (en) * | 2001-01-10 | 2001-11-14 | 刘从清 | Yinkang lotion |
| CN1768829A (en) * | 2004-11-05 | 2006-05-10 | 郭连英 | Chinese medicine for treating tuberculosis |
| CN102920810A (en) * | 2012-11-20 | 2013-02-13 | 汉仲月 | Mucosa nursing matter for behcet's syndrome |
| CN103285284A (en) * | 2013-07-01 | 2013-09-11 | 庄兰兰 | Medical composition for treating senile vaginitis |
| CN103301353A (en) * | 2013-07-01 | 2013-09-18 | 刘晓晖 | Pharmaceutical composition for treating atrophic vaginitis |
| CN103301373A (en) * | 2013-07-01 | 2013-09-18 | 丁霄雁 | Pharmaceutical composition for treating postpartum perineal mucosal lesions |
| CN103301374A (en) * | 2013-07-01 | 2013-09-18 | 巩春梅 | Pharmaceutical composition for treating postpartum non-specificity vaginitis |
| CN103330896A (en) * | 2013-07-01 | 2013-10-02 | 巩春梅 | Preparation method of powder for treating postpartum nonspecific vaginitis |
| CN103356932A (en) * | 2013-07-01 | 2013-10-23 | 张世叶 | Medicine composition for treating vulva squamous cell hyperplasia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103316270B (en) | 2015-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN104258066A (en) | Traditional Chinese medicine preparation for treating kidney-yin deficiency-type dysfunctional uterine bleeding, and preparation method thereof | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN103055285A (en) | Traditional Chinese medicine for treating forepart hepetocirrhosis and preparation method thereof | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN103356932B (en) | A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia | |
| CN105233188A (en) | Traditional Chinese medicine composition for treating liver cancer and application of traditional Chinese medicine composition | |
| CN103301373B (en) | Pharmaceutical composition for treating postpartum perineal mucosal lesions | |
| CN104689279A (en) | Traditional Chinese medicine preparation for adenomyosis of uterus and preparation method thereof | |
| CN103330867B (en) | Preparation method of powder for treating senile vaginitis | |
| CN103239692B (en) | Chinese medicine liniment for treating skin itch and preparation method of Chinese medicine liniment | |
| CN103316270B (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN104887950A (en) | Mastitis treatment traditional Chinese medicine compound | |
| CN103330896B (en) | Preparation method of powder for treating postpartum nonspecific vaginitis | |
| CN103301374B (en) | Pharmaceutical composition for treating postpartum non-specificity vaginitis | |
| CN103341094B (en) | Preparation method of powder for treating vulva squamous epithelial cell hyperplasia | |
| CN103285300A (en) | Medicinal composition for treating stress incontinence | |
| CN102552824B (en) | Traditional Chinese medicine prepared prescription for treating psoriasis | |
| CN102205067A (en) | Traditional Chinese medicine composition for treating chronic urticaria | |
| CN105125964A (en) | Traditional Chinese medicine preparation for treating pelvic peritonitis and preparation method thereof | |
| CN105232997A (en) | Chinese herba preparation used for treating endometritis and preparing method | |
| CN104922595A (en) | Traditional Chinese medicinal preparation for herpes zoster and preparation method thereof | |
| CN104758539A (en) | Traditional Chinese medicine composition for treating debilitation | |
| CN103301354B (en) | Preparation method of powder for treating infantile vaginitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANG CHUNJIE Effective date: 20150210 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ding Xiaoyan Inventor after: Jiang Chunjie Inventor before: Ding Xiaoyan Inventor before: Feng Tao Inventor before: Geng Hui |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: DING XIAOYAN FENG TAO GENG HUI TO: DING XIAOYAN JIANG CHUNJIE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150210 Address after: 255036 Zibo Central Hospital, Shandong, Shandong, China, Zhangdian, No. 54, No. Applicant after: Ding Xiaoyan Applicant after: Jiang Chunjie Address before: 255036 Zibo Central Hospital, Shandong, Shandong, China, Zhangdian, No. 54, No. Applicant before: Ding Xiaoyan |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150318 Termination date: 20150701 |
|
| EXPY | Termination of patent right or utility model |